Skip to main content

Psoriasis News

A recent study demonstrated the safety and long-term effectiveness of bimekizumab, with participants maintaining high PASI scores through 60 weeks of treatment.
Findings from a recent study showed that satisfaction with physicians is associated with mental health comorbidities among patients with psoriasis.
Using data from a large registry, researchers investigated the real-world safety of several systemic medications including etanercept, secukinumab, ustekinumab, and apremilast.
Findings from a recent systemic review showed some biologic medications may be effective for patients with erythrodermic psoriasis.
A recent meta-analysis highlighted several biologics that were associated with higher short-term and long-term PASI 75, PASI 90, and PASI 100 response rates.
Findings from a recent study showed an NK1 receptor antagonist may be an effective, new option for patients with psoriatic pruritus.
Results from a small retrospective study suggest adding apremilast to biologic therapy may be a safe and effective option for biologic fatigue among patients with psoriasis.
In a recent study that assessed the impact of metabolic conditions on health care costs and treatment outcomes for biologics and apremilast, the researchers found patients with psoriasis and metabolic conditions had higher rates of switching and discontinuation.
Findings from a recent study showed a biologic was still safe and effective among patients with psoriasis and metabolic syndrome.
A recent nationwide population-based cohort study investigated the impact of body weight variability on the risk of developing psoriasis.
Back to Top